Design your genetically modified bacterial strains and expression vectors – with reliable solutions tailored to your needs.
For more than 15 years, Smaltis has applied its expertise in genetic engineering to tailor bacterial genomes and construct expression plasmids.
Through our two business units – Research Microbiology and Precision Microbiology – we provide complete and rigorous services, from the initial strain or vector to the delivery of compliant, ready‑to‑use material.
• Study of compound mechanism of action or interactions with a strain
• Gene expression analysis
• Protein functionality evaluation
• Verification of diagnostic kit performance
• Development of reporter/biomarker systems
• Productivity improvement
• Contaminant elimination
• Process simplification
• Reproduction of “free‑to‑use” mutants
• Expression system modification
• Generation of “safe‑to‑use” strains
OUR SOLUTIONS
Genome modification by deletion, replacement, insertion, or site‑directed mutagenesis
Plasmid construction & optimization: design, cloning, expression control, production
Proprietary Mutants Available:
– Escherichia coli BL21 deleted for DE3 phage genes (“animal‑free”)
– Pseudomonas aeruginosa PAO1, hypersensitive to antibiotics and hypovirulent
Our Promise: Cutting‑edge technology serving your genome
They trust us
Testimonials and references
Clara LEANDRO Head of Infection
TECHNOPHAGE
The advancement of Technophage's therapeutic pipeline products has received crucial support from SMALTIS in the scope of genetic modification of bacterial strains. Throughout this collaborative effort, the SMALTIS scientific team has demonstrated remarkable commitment to resolving various technical challenges, successfully aligning with our objective of acquiring a set of strains for our internal utilization, all within the stipulated timeline.
Laurence RINGENBACH Cell Biology Lab Manager,
Immunodiagnostic Reagents,
DIACLONE SAS part of Medixbiochemica
Smaltis is a long-term partner with whom we have established a privileged relationship. We work in highly complementary domains and collaborate regularly to provide a comprehensive offering to our clients, utilizing microbiology and molecular biology services that we specifically require. We engage them for services such as sample contamination analysis, production of competent bacteria, and preparation of suspensions of inactivated strains for the development of new monoclonal antibodies. A true bond of trust has developed, facilitated by the geographical proximity of our respective locations and easy communication with their teams, whose flexibility, tenacity in problem-solving, and quality of work are crucial for us.
Thomas GLOUDEN PCR Development Expert
UNISENSOR
As part of the development of a simple, rapid molecular test for the detection of certain pathogenic micro-organisms in milk, we needed to work with a company with expertise in microbiology. We were looking for a qualified and experienced laboratory to prepare calibrated microbial suspensions and purified genetic material from different bacterial species. By identifying Smaltis, we were able to fully achieve our objectives thanks to the expertise of their team. We now regularly rely on this trusted partner for our recurring needs.
Caroline GEBUS Microbiology Quality Control
OM Pharma
We use Escherichia coli strains to manufacture our Uro-Vaxom® product for the prevention of recurrent lower urinary tract infections and co-treatment of acute urinary tract infections and, in accordance with regulatory requirements, we must demonstrate the stability of our strains. We therefore asked SMALTIS to develop a tailor-made quality control method. In addition to their ability to listen to customer needs and propose new ideas, the SMALTIS team has also distinguished itself by the quality and accuracy of its analysis reports. At present, the partnership established with SMALTIS is a real asset for OM Pharma.
Olivier DHELLIN Director of Pharmaceutical Development
NEOVACS
During our program to develop and industrialize the production of our Kinoïdes® vaccines, SMALTIS has proven to be a partner of choice for optimizing one of our cytokine production systems. Its service consisted in optimizing the genetic heritage of the host bacterium by excising DNA from exogenous sequences. Very attentive and with a rare expertise in microbiology, the SMALTIS team has always been benevolent and has never hesitated to guide us by providing sound advice. It is with pleasure that we will again call upon the services of SMALTIS to help us in our next challenges.
Elise JACQUIN Associate Professor in Cell Biology
Unité CTM, Inserm U1231, Université de Bourgogne
To test the impact of mutations identified in cancer patients, we needed to reproduce them in an expression plasmid in order to measure their effects in cell transfection models. So we turned to Smaltis and their expertise in genetic engineering. The team understood our needs perfectly, and was able to efficiently implement the directed mutagenesis strategy to obtain the desired plasmids, while guaranteeing their high quality. As a result, we were able to rapidly carry out test manipulations, which proved conclusive and enabled us to obtain the preliminary data needed to submit a major funding application. We were fully satisfied with the team's professionalism in managing this project, and with the regular and easy exchanges of information on the progress of the manipulations. We look forward to working with Smaltis again in the future.
News and articles
New Offer Structure: 2 Business Units Supporting Your Projects
At Smaltis, our ambition remains unchanged: bringing microbiological excellence to your innovations.
To better address the diversity of your needs, we have structured our offer around 2 complementary Business Units, true pillars of our scientific and technical commitment.
Malassezia: Cultivating the Invisible – A Challenge Met
Some yeasts are particularly resistant… especially Malassezia restricta.
This lipophilic yeast, naturally present on human skin, is involved in various imbalances of the skin microbiota, notably those linked to dandruff or seborrheic dermatitis. But cultivating it in the laboratory is no easy task!
Once upon a time was cheese, a high place of communication between fungi and bacteria.
Attracted by the smell of French cheeses, a team from Tufts University published work on how, in Camembert, Roquefort and other festivities, bacteria use compounds produced by fungi and adapt their behavior.
Once upon a time, the English bacteriologist Ernest Hankin demonstrated for the first time the presence of anti-bacterial entities in the waters of Indian rivers, putting humanity on the path to a promising anti-infectious therapy that is more relevant than ever.
Smaltis attends the 34th edition of the ECCMID international congress, renamed ESCMID Global, in Barcelona from April 27 to 30, 2024. This clinical microbiology and infectious diseases event is one of the largest and most important congresses in the field of infection, bringing together over 16,000 participants from all over the world to contribute to the dissemination of scientific knowledge.
Smaltis attends the Sanofi Vaccines R&D Day, organized by Sanofi in partnership with Lyonbiopôle, Enosis Santé and Polepharma!
This event aims to foster partnerships around 5 themes: antimicrobial approaches, therapeutic vaccines and antibodies, mucosal or skin delivery of vaccines, immunology, and antigen design. Quite a program!
Cédric Muller will be present at this event, which will take place on April 11, 2024, at 14 Espace Henry Vallée in Lyon.
Smaltis is delighted to be taking part in the 7th edition of Microbiota & Health Day, organized by Lyonbiopôle and Alliance Promotion Microbiote, on March 26, 2024 in Lyon. The aim of this day is to bring together academic, clinical and industrial players to discuss topical issues that are driving innovation in the field of microbiota and their impact on health.
Smaltis is happy to participate to the 8th edition of AMR Conference in Basel from March 6th to 7th 2024, a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and specific challenges faced by the innovation ecosystem in bringing new antimicrobial treatments and diagnostics to the market.
The year 2024 marks the 10th anniversary (already!) of the Smaltis adventure! 10 years of microbiology, 10 years of molecular biology, 10 years of passion, 10 years of twists and turns, 10 years of growth, 10 years of self-reflection, 10 years of continuous improvement, 10 years of scientific spirit, 10 years of ambition, 10 years of collaboration, 10 years of human relationships…
It was necessary to celebrate this milestone, and not just by blowing out the candles.
Smaltis is delighted to have participated in and sponsored, for the fourth consecutive year, the Polepharma Microbiomics Days, held in Rouen on November 22 and 23, 2023.